HBM Exercises Pre-Funded Warrants, Solidifying 12.5% Stake in Chemomab
CMMB sits 96% above its 52-week low of $1.35.
Summary
HBM Healthcare Investments exercised its pre-funded warrants to acquire 80,971,680 ordinary shares of Chemomab, ensuring it can vote its full 12.5% stake in favor of the pending Scipher Medicine merger.
Key Events · Ownership and Investor Activity · CMMB
-
Warrant Exercise Completed
HBM exercised its pre-funded warrants on September 7, 2026, converting them into 80,971,680 ordinary shares (represented by ADSs).
-
Voting Obligation Fulfilled
The exercise was made to effectuate HBM's voting obligations under the Shareholder Support Agreement related to the pending Scipher Medicine merger.
-
Ownership Stake Confirmed
HBM now holds 80,971,680 ordinary shares, representing 12.5% of Chemomab's outstanding shares, with sole voting and dispositive power.
-
Merger Support Strengthened
The warrant exercise removes any doubt about HBM's ability to vote its full stake in favor of the merger, supporting the deal's completion.
Analysis · CMMB · Life Sciences
HBM Healthcare Investments converted its pre-funded warrants into 80,971,680 ordinary shares on September 7, 2026, fulfilling its voting obligations under the Shareholder Support Agreement tied to the pending Scipher Medicine merger. This exercise removes uncertainty about HBM's ability to vote its full 12.5% stake in favor of the merger, a critical step toward closing the deal. The conversion is non-dilutive to existing shareholders because the warrants were pre-funded and already reflected in the ownership structure, but it confirms HBM's commitment to the merger.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMMB was trading at $2.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.9M. The 52-week trading range was $1.35 to $3.58. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.